



PRESS RELEASE

Zutphen, the Netherlands, 6 November 2014

Esperite N.V. convenes EGM to change auditor

Esperite N.V. (Euronext: ESP, 'Esperite', or 'the Group'), the European leader in stem cells cryopreservation, now entering the fields of predictive medicine and translational regenerative medicine R&D, announces it is convening an extra-ordinary general meeting of shareholders ("EGM") to be held on Thursday 18 December 2014 to change its auditor.

On 14 May 2014 the shareholders meeting appointed KPMG Accountants N.V. as external auditor for a term of 1 year. Since the 14 May 2014 appointment, however, the Company has not been able to agree appropriate fees for the 2014 audit with KPMG. The fees proposed by KPMG represent a substantial increase in comparison with its previous audits of the Company's annual financial statements, with the Company disagreeing with the argumentation that KPMG provided as justification for this increase. Furthermore, KPMG's fee proposal was much higher than other reputable audit firms have proposed to the Company during a tender audit process it has conducted.

Also given the Company's cost cutting exercise and stringent cash management, the Board of Directors is of the opinion that maintaining KPMG as the external auditor in relation to the 2014 audit is no longer justified or appropriate. Consequently, the Board of Directors proposes that the EGM withdraws the 14 May 2014 appointment of KPMG Accountants N.V. as the Company's external auditor, and instead appoints EY Accountants LLP as external auditor for a term of 1 year. Appointing EY Accountants LLP as the Company's external auditor for the 2014 audit will result in substantially lower 2014 audit costs than such costs would have amounted to if KPMG were to conduct the 2014 audit on the basis of its fee proposal.

The EGM's convocation notice, agenda and the explanatory notes to the agenda are available free of charge at the Company's offices in Zutphen, the Netherlands and can be downloaded from the Company's website, www.esperite.com.

Enquiries: Esperite
Frédéric Amar, Chief Executive Officer

+ 31 (0) 575 548 998

About Esperite (www.esperite.com)

Esperite, the leading international company in regenerative and predictive medicine. Its family stem cell bank, CryoSave, stores almost 275,000 samples from umbilical cord blood and cord tissue. There are already many diseases treatable by the use of stem cells, and the number of treatments will only increase. Esperite has cryopreserved samples from over 70 countries on six continents, with ultra-modern processing and storage facilities in Belgium, Switzerland, Germany, Dubai, South Africa and Portugal.